Nasdaq:US$18.73 (+0.01) | HKEX:HK$30.75 (+1.05) | AIM:£2.96 (-0.08)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 6 Apr 2013

AACR 2013: HMPL-504 (savolitinib), a novel, selective and potent cMET inhibitor, is efficacious in primary tumor models of cMET-driven gastric cancer